Studies of radiomics have been used in head and neck, and lung cancers to identify prognostic phenotypes,2 predict clinical outcomes in early‐stage non‐small cell lung cancer (NSCLC) patients treated with stereotactic body radiation therapy,3 and assist in immunotherapy by estimating CD8 cell infiltration into the tumor and predicting clinical outcomes.4, 5. The gene discussed is CD8A; the disease is lung cancer.